A Phase 3 study of SY-2101 in patients with newly diagnosed acute promyelocytic leukemia (APL)

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 12 Jan 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

09 Jan 2023 According to a Syros Pharmaceuticals media release, the company plans to provide timing for further evaluation of SY-2101 in a registration enabling study in APL in the second half of 2023.
05 Jul 2022 According to a Syros Pharmaceuticals media release, company expects to initiate this trial in the second half of 2023.
10 Jan 2022 According to a Syros Pharmaceuticals media release, company expects to initiate the Phase 3 trial in the first quarter of 2023 and to announce data in 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com